Liminatus Pharma, Inc. (LIMN)
Nasdaq · Healthcare · Biotechnology
$3.99+2.31%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $5.4M
- 52-week range
- $3.29 – $141.50
- 52-week change
- −95.06%
- EPS (trailing)
- −$23.50
Fiscal year to Dec 2025
- Net income
- −$10.2M
- Diluted EPS
- −$0.43
- Free cash flow
- −$10.0M
From the company’s annual report on SEC EDGAR.
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Headquarters: Cerritos, United States · 1 employees · liminatuspharma.com